Dr. Patrick V.J.J Vink M.D. serves as Independent Director of the Company. Dr. Vink has served on our board of directors since September 2015. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and non-executive board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc. Most recently he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company’s profit and loss. He joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester.
As the Independent Director of Spero Therapeutics Inc, the total compensation of Patrick Vink at Spero Therapeutics Inc is $97,874. There are 10 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.
Patrick Vink is 56, he's been the Independent Director of Spero Therapeutics Inc since 2015. There are 9 older and 10 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.
Patrick's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela, and Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Spero Therapeutics Inc executives and other stock owners filed with the SEC include: